BIOMAT Database Logo BIOMAT Database Logo

Low-dose cytosine arabinoside in myelodysplastic syndromes. 1989

P Mineur, and P Martiat, and A Ferrant, and J L Michaux

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

P Mineur, and P Martiat, and A Ferrant, and J L Michaux
Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes.
October 1984, British journal of haematology,
P Mineur, and P Martiat, and A Ferrant, and J L Michaux
Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia.
September 1985, Cancer,
P Mineur, and P Martiat, and A Ferrant, and J L Michaux
High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
January 1995, Hematologic pathology,
P Mineur, and P Martiat, and A Ferrant, and J L Michaux
Low dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromes.
July 1988, Irish journal of medical science,
P Mineur, and P Martiat, and A Ferrant, and J L Michaux
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
August 1985, Cancer,
P Mineur, and P Martiat, and A Ferrant, and J L Michaux
The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
November 1989, Cancer,
P Mineur, and P Martiat, and A Ferrant, and J L Michaux
Low-dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia and myelodysplastic syndromes.
June 1985, Seminars in oncology,
P Mineur, and P Martiat, and A Ferrant, and J L Michaux
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
January 1987, Haematologica,
P Mineur, and P Martiat, and A Ferrant, and J L Michaux
Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
July 1989, Journal of chemotherapy (Florence, Italy),
P Mineur, and P Martiat, and A Ferrant, and J L Michaux
Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
March 1996, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!